Atazanavir/ritonavir: A valuable once-daily HIV protease inhibitor with little impact on lipid profile

Future Virology

Volumn 2, Issue 2, 2007, Pages 131-143

  Gianotti, Nicola ^a   Lazzarin, Adriano ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

AIDS; Antiretroviral therapy; Atazanavir ritonavir; HIV; HIV protease inhibitor; HIV resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CLARITHROMYCIN; CYTOCHROME P450 3A4; DARUNAVIR; DILTIAZEM; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; JAUNDICE; LIPODYSTROPHY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PARESTHESIA; PATIENT COMPLIANCE; PR INTERVAL; PREGNANCY; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; RECOMMENDED DRUG DOSE; SCLERA DISEASE; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

EID: 34249322005     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.2.131     Document Type: Article

References (47)

1. Palella FJ Jr, Baker RK, Moorman AC et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the hiv outpatient study. J. Acquir. Immune Defic. Syndr. 43, 27-34 (2006).
2. May MT, Sterne JA, Costagliola D et al.: HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368, 451-458 (2006).
3. Hammer SM, Saag MS, Schechter M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843 (2006).
4. Sollima S, Osio M, Muscia F et al.: Protease inhibitors and erectile dysfunction. AIDS 15, 2331-2333 (2001).
5. Collazos J, Martinez E, Mayo J, Ibarra S: Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31, 322-326 (2002).
6. Thomas J, Dohetty SM: HIV infection a risk factor for osteoporosis. J. Acquir. Immune Defic. Syndr. 33, 281-291 (2003).
7. Amorosa V, Tebas P: Bone disease and HIV infection. Clin. Infect. Dis. 42, 108-114 (2006).
8. Havlir DV, O'Marro SD: Atazanavir: new option for treatment of HIV infection. Clin. Infect. Dis. 38, 1599-1604 (2004).
9. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005).
10. Agarwala S, Eley T, Filoramo et al.: Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment naive HIV-infected patients. Proceedings of the 7th International Workshop of Clinical Pharmacology. Lisbon, Portugal (2006) (Abstract 85).
11. Agarwala S, Grasela D, Child M, Geraldes M, Geiger M, O'Mara E: Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval. Proceedings of: the 2nd JAS Conference on Pathogenesis and Treatment. Paris, France (2003) (Abstract 845).
12. O'Mara E, Cirincione B, Mummaneni V, Grasela T, Grasela D: Population pharmacodynamic (PD) assessment of the safety and antiretroviral activity of atazanavir (BMS-232632). Proceedings of: the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL (2001) (Abstract A-507).
13. Lukiana T, Poirier J, Meynard J et al.: Therapeutic drug monitoring of atazanavir (ATV) in the French prospective cohort 'Pharmataz'. Proceedings of the XVI International AIDS Conference. Toronto, Canada (2006) (Abstract TUPE0100).
14. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24, 1732-1747 (2004).
15. Kaul S, Bassi K, Damle B et al.: Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003) (Abstract A-1616).
16. 2-receptor antagonists with atazanavir. J. Acquir. Immune Defic. Syndr. 42, 516 (2006).
17. Ribera E, Azuaje C, Lopez RM et al.: Atazanavir and lopinavir/ ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20, 1131-1139 (2006).
18. Colombo S, Buclin T, Franc C et al.: Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir. Ther. 11, 53-62 (2006).
19. Bloch M, Quan D, Kaufmann G et al.: Pharmacokinetics, tolerability and therapeutic response of double boosted protease inhibitor (PI) antiretroviral (ARV) therapy with lopinavir/ritonavir/and atazanavir administered once (od) and twice daily (bd) in patients with HIV-1 infection. Proceedings of: the XVI International AIDS Conference. Toronto, Canada (2006) (Abstract TUPE0075).
20. Boffito M, Kurowski M, Kruse G et al.: Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18, 1291-1297 (2004).
21. Winston A, Bloch M, Carr A et al.: The Clinical Correlations of Trough Plasma Atazanavir Levels in a Cohort of HIV-1-positive Individuals Receiving HAART. Proceedings of: the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005) (Abstract 656).
22. Kurowski M, Breske A, Lehmann S, Kruse G, Eskoetter H: Plasma concentrations of atazanavir in HIV patients treated with regimens including nevirapine. Proceedings of: the XVI International AIDS Conference. Toronto, Canada (2006) (Abstract CDB0459).
23. Persico M, Persico E, Bakker CT et al.: Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology 33, 627-632 (2001).
24. Rotger M, Taffe P, Bleiber G et al.: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192, 1381-1386 (2005).
25. Rodriguez Novoa S, Barreiro P, Rendon A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C>T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42, 291-295 (2006).
26. Ray JE, Marriott D, Bloch MT, McLachlan AJ: Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br. J. Clin. Pharmacol. 60, 291-299 (2005).
27. Robinson BS, Riccardi KA, Gong YF et al.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093-2099 (2000).
28. Gong Y, Eggers B, Yang H et al.: Atazanavir susceptibility spectrum extends to HIV-1 non-B subtypes and HIV-2 viral isolates. Proceedings of: the XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Sitges, Spain (2006) (Abstract 90).
29. Gong YF, Robinson BS, Rose RE et al.: In Vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44, 2319-2326 (2000).
30. Colonno RJ, Thiry A, Limoli K, Parkin N: Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. 47, 1324-1333 (2003).
31. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J: Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189, 1802-1810 (2004).
32. McGrath D, Hammond J, Frederick D, Mathew M, Kastango K, McLaren C: Evaluation of resistance patterns in treatment-naïve subjects with virological failure on atazanavir- or atazanavir/ritonavir-containing regimens. Proceedings of: the XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Sitges, Spain (2006) (Abstract 87).
33. Kempf DJ, King MS, Bernstein B et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189, 51-60 (2004).
34. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W: GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 18, 651-655 (2004).
35. Eron J Jr, Yeni P. Gathe J Jr et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368, 476-482 (2006).
36. Malan N, Krantz E, David N et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Proceedings of: the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006) (Abstract 107LB).
37. Swindells S, DiRienzo AG, Wilkin T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296, 806-814 (2006).
38. Johnson M, Grinsztejn B, Rodriguez C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20, 711-718 (2006).
39. Keiser P McGrath S, Reynolds L et al.: Changes in lipid profiles in treatment-experienced patients switched to atazanavir-based antiretroviral therapy: results from the atazanavir expanded access program (EAP). Proceedings of: the XVI International AIDS Conference. Toronto, Canada (2006) (Abstract WEPE0163).
40. Noor MA, Flint OP, Maa JF, Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 20, 1813-1821 (2006).
41. Busti AJ, Isikouris JP, Peeters MJ et al.: A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Medicine 7, 317-322 (2006).
42. Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Proceedings of: the 3rd IAS Conference on Pathogenesis and Treatment. Rio de Janeiro, Brasil (2005) (Abstract TuPe5.2P01).
43. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 20, 847-853 (2006).
44. Vora S, Perrin L, Yerly S et al.: Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20, 35-40 (2006).
45. Pellegrin I, Breilh D, Ragnaud JM et al.: Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir. Ther. 11, 421-429 (2006).
46. Bertoli A, Santoro M, Lorenzini P et al.: Different pattern of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients. Proceedings of: the XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Sitges, Spain (2006) (Abstract 89).
47. Johnson M, Grinsztejn B, Rodriguez C et al.: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19, 685-694 (2005).